Cited 10 times in
Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이종수 | - |
dc.contributor.author | 장원식 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 함원식 | - |
dc.contributor.author | 허지은 | - |
dc.date.accessioned | 2021-09-29T01:17:12Z | - |
dc.date.available | 2021-09-29T01:17:12Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184289 | - |
dc.description.abstract | Background: This study investigated patient outcomes after urinary diversion in order to manage malignant ureteral obstruction caused by non-urologic cancers and to evaluate predictive factors for overall survival. Methods: The study retrospectively reviewed patients with non-urologic malignancies who underwent ureteral stenting or percutaneous nephrostomy for ureteral obstruction between 2006 and 2014. The variables for predicting overall survival were identified by Cox regression analysis. Results: The study enrolled 778 patients, including 522 patients who underwent ureteral stenting and 256 patients who underwent percutaneous nephrostomy. Renal function was assessed immediately and then 2 weeks after urinary diversion. The median survival period was 5 months (interquartile range [IQR] 2-12 months). A total of 708 patients died. The patients who received chemotherapy after urinary diversion had a survival gain of 7 months compared with the patients who did not receive subsequent chemotherapy (p < 0.001). The survival rate did not differ between the various types of urinary diversion (p = 0.451). In the multivariate analysis, lower survival rates were significantly associated with male sex; previous chemotherapy without radiotherapy; an increasing number of events related to malignant dissemination; low preoperative hemoglobin (< 10 mg/dL), albumin (< 3 g/dL), and estimated glomerular filtration (< 60 mL/min/1.73 m2) rates; and no subsequent chemotherapy or radiotherapy. Conclusions: In cases of ureteral obstruction caused by non-urologic malignancies, the overall survival was poor. However, the patients who received chemotherapy after urinary diversion had a survival gain of 7 months. Therefore, urinary diversion could be considered to preserve renal function for subsequent chemotherapy, whereas patients with the poor prognostic factors should be presented with the option of no intervention. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | ANNALS OF SURGICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasms* / complications | - |
dc.subject.MESH | Nephrostomy, Percutaneous* / adverse effects | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stents | - |
dc.subject.MESH | Ureter* | - |
dc.subject.MESH | Ureteral Obstruction* / etiology | - |
dc.subject.MESH | Ureteral Obstruction* / surgery | - |
dc.subject.MESH | Urinary Diversion* / adverse effects | - |
dc.title | Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Ji Eun Heo | - |
dc.contributor.googleauthor | Dae Young Jeon | - |
dc.contributor.googleauthor | Jongsoo Lee | - |
dc.contributor.googleauthor | Won Sik Ham | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Won Sik Jang | - |
dc.identifier.doi | 10.1245/s10434-020-09423-4 | - |
dc.contributor.localId | A05500 | - |
dc.contributor.localId | A05268 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04337 | - |
dc.contributor.localId | A05531 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 33389298 | - |
dc.identifier.url | https://link.springer.com/article/10.1245%2Fs10434-020-09423-4 | - |
dc.contributor.alternativeName | Lee, Jong Soo | - |
dc.contributor.affiliatedAuthor | 이종수 | - |
dc.contributor.affiliatedAuthor | 장원식 | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.contributor.affiliatedAuthor | 함원식 | - |
dc.contributor.affiliatedAuthor | 허지은 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 2367 | - |
dc.citation.endPage | 2373 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL ONCOLOGY, Vol.28(4) : 2367-2373, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.